Skip to content


  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page

Price hangs on patient outcomes

Andrew Jack
Financial Times
4 May 2010

PA health systems expert Steve Black has been quoted in the Financial Times.  Steve gives his views on the implications of a new model of payment by results which is emerging in healthcare. 

Commenting on the process of linking pharmaceutical prices more closely to patient outcomes, Steve says: “It is not uncommon for some classes of drugs to be effective in only one in three patients who take them.”

Steve cites anti-cancer treatments and psychoactive medicines as examples and concludes: “We might have to spend tens of thousands before knowing whether a drug will have any effect."

You can read Steve's views on data management here

To visit PA's heathcare pages, click here

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.